UroGen Pharma Ltd. — Director's Dealing 2025

Aug 27, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2025-08-26

Reporting Person: Belldegrun Arie (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-26	Stock Option (right ot buy)	$19.50	A	20000	Acquired	2035-08-26	Ordinary Shares (20000)	Direct

Footnotes

F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.